ArticleFrontiers in genetics2026
Identification and prenatal diagnosis of a novel likely pathogenic ANOS1 variant in a large Chinese Kallmann syndrome family.
Article in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to systematically analyze a Chinese family with Kallmann syndrome (KS), evaluate the pathogenicity of a candidate variant through co-segregation analysis and bioinformatic predictions, and provide clinical intervention for the family. Methods: This study included a Chinese family with KS comprising 40 members in total (37 living, 3 deceased). Whole-genome sequencing (WGS) was performed on the proband, followed by Sanger sequencing for co-segregation analysis with 22 family members. Multiple bioinformatics tools were used to assess evolutionary conservation, and AlphaFold3 modeling was employed to predict the potential impact on protein structure. Based on the genetic findings, prenatal diagnosis was subsequently offered to and performed for a female carrier in the family. Results: A hemizygous ANOS1:c.1879T>C (p.Ser627Pro) variant was identified. Among the eight males with clinical features of KS in this family, five of whom underwent genetic testing, and all carried the variant. The variant fully co-segregated with KS among the genotyped individuals: all five tested males carried the variant (with their mothers confirmed as carriers), while five unaffected male relatives were wild-type. Bioinformatics analysis predicted that the variant site is evolutionarily conserved across species. AlphaFold3 modeling further suggested that the p. Ser627Pro substitution disrupts the original hydrogen bonding network, potentially leading to protein instability and function impairment. Based on these genetic findings, prenatal diagnosis was performed for a female carrier in the family, and the results showed that the fetus did not carry the variant. Conclusion: Combining family co-segregation (PP1) and population frequency data (PM2), the ANOS1 c.1879T>C variant was classified as likely pathogenic, providing important information for genetic counseling. This study demonstrated that even in the absence of functional experiments, comprehensive family analysis can provide crucial clues for variant of uncertain significance (VUS) interpretation. This study also guided prenatal diagnosis, offering a referable strategy for the management of similar rare diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.